Every material Form 8-K CG Oncology, Inc. has filed with the SEC since May 08, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
CG Oncology reported a third-quarter 2026 net loss of $56.9 million, or $(0.64) per share, up from $43.8 million, or $(0.57) per share, a year earlier. Total revenue was $1.6 million, down from $1.7 million, while research and development expenses rose to $39.2 million from $27.9 million. Cash, cash equivalents and marketable securities were $984.5 million at September 30, 2026, which the company expects will fund operations through 2029.
Net loss of $56.9 million, or $(0.64) per share, for the quarter ended September 30, 2026, versus $43.8 million, or $(0.57) per share, a year earlier
Total revenue of $1.6 million, compared with $1.7 million in the prior-year quarter
Research and development expenses of $39.2 million, up from $27.9 million, mainly due to higher clinical trial costs and headcount-related compensation
PIVOT-006 Phase 3 topline data expected November 2026; BLA completion for BCG-unresponsive NMIBC expected in Q4 2026
CG Oncology reported a second-quarter 2026 net loss of $79.1 million, or $(0.90) per share, up from $41.4 million, or $(0.54), a year earlier, on revenue of $1.2 million. The company also filed an amendment to increase by $500.0 million the shares it can sell under its Jefferies at-the-market sale agreement, which could add to dilution for existing shareholders.
Q2 2026 net loss was $79.1 million, or $(0.90) per share, versus $41.4 million, or $(0.54) per share, in Q2 2025.
Research and development expenses were $54.7 million, compared with $31.3 million a year earlier.
Cash, cash equivalents and marketable securities were $1.0 billion as of June 30, 2026, down from $1.1 billion as of March 31, 2026.
Amendment No. 2 adds $500.0 million of shares available under the Jefferies sale agreement dated March 28, 2025, after about $550.0 million was previously sold.
CG Oncology agreed on May 20, 2026 to the separation of President and Chief Operating Officer Ambaw Bellete, effective June 30, 2026. Arthur Kuan was appointed President in addition to his existing roles, and the company has started a search for a Chief Commercial Officer, which matters to shareholders because it changes senior leadership and the executive team responsible for commercial operations.
Ambaw Bellete, President & Chief Operating Officer, separation effective June 30, 2026
Separation agreement expected to include a general release and the severance set forth in Section 4(b) of his employment agreement
Arthur Kuan appointed President on May 20, 2026, in addition to his other positions
Company has initiated a search for a Chief Commercial Officer
CG Oncology reported a first-quarter 2026 net loss of $60.2 million, or $(0.71) per share, up from $34.5 million, or $(0.45) per share, a year earlier, while total revenues rose to $1.1 million from $52 thousand. The company says it expects to complete its BLA submission for HR BCG-unresponsive NMIBC in the fourth quarter of 2026, and it ended the quarter with about $1.1 billion in cash, cash equivalents and marketable securities.
Net loss was $60.2 million, or $(0.71) per share, versus $34.5 million, or $(0.45) per share, in Q1 2025.
Total revenues were $1.1 million versus $52 thousand; R&D expenses rose to $43.7 million from $27.5 million.
Cash, cash equivalents and marketable securities were $1.1 billion at March 31, 2026, including about $391.4 million of net at-the-market facility proceeds in Q1.
BLA completion is expected in the fourth quarter of 2026, and PIVOT-006 Phase 3 topline data is anticipated in the first half of 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every CG Oncology, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →